The Society for Immunotherapy of Cancer (SITC) hosted Session 106d during the 39th Annual Meeting & Pre-Conference Programs on Friday, November 8, 2024. Available here are the presentation slides and video from “Session 106d: Biotech Breakthroughs - Solid Tumor IO at the Tipping Point” as permitted by presenters.
Kristen Hege, MD
Zhen Su, MD, MBA – Marengo Theraputics
Cancer immunotherapy has transformed cancer care over the past decade with more than 25 FDA approved medicines in the clinic. Immune activation focused novel modalities have demonstrated compelling efficacy and achieved regulatory approvals in hematologic malignancies over the past decade. Beyond the first wave T cell checkpoint blockade, developing next wave novel IO therapeutics in solid tumor have been challenging, but the tide has turned. 2024 is a breakthrough year for new and pending FDA approvals of both cell therapies and complex biologics in multiple solid tumor indications focusing on reinvigorating the anti-tumor immune response. In this session you will learn about the development and commercial launch of these exciting new immuno-oncology products including tumor infiltrating lymphocytes, T cell receptor engineered T cells, T cell engaging bispecific antibodies, next generation cytokines and more.
To view the entire program schedule (including presenter permission to post) please click here.
01:34:04